So, for a time line (opmistically), it looks like we have FDA approval for Rida in Sarcoma in the first half of 2012, and the FDA NDA filing in the second half of 2012 for Ponat. Don, without partnering in the EU and Asia for Ponat, isn't one more dilution needed for Ariad to make it to the promised land?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.